Addressing Unmet Needs in the Treatment of Primary Sjögren's Syndrome: Expert Insight on the Therapeutic Potential for CD40 Pathway Blockade



Date & Location
Tuesday, November 30, 2021, 3:00 PM - Tuesday, November 22, 2022, 11:59 PM

Credits
AMA PRA Category 1 Credits™ (0.50 hours), AMA PRA Category 1 Credits™ Designated (0.50 hours)

Target Audience
Specialties - Internal Medicine, Otolaryngology, Primary Care, Rheumatology
Professions - Non-Physician, Nurse, Nurse Practitioner, Other Healthcare Professionals, Physician, Physician Assistant, Physician In Training, Resident Physician

Overview

In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future.


Registration

There are no fees for participating in and receiving CME credit for this online activity.

To view this activity, click here, or visit the content tab.



Objectives

As a result of participating in this activity, participants should be able to:


  1. Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome;
  2. Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment;
  3. Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome;
  4. Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Accreditation

The University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of .50 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.


Additional Information

Disclosure of Ineligible Relationship (COI) Policy

In accordance with the ACCME Standards for Integrity and Independence and the University of Cincinnati policy, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies (commercial interest) within the last 24-months. The ACCME requires us to disqualify individuals who refuse to provide this information from involvement in the planning and implementation of accredited continuing education. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence.

Medical Director & Program Planners

PVI, PeerView Institute for Medical Education
Margery Tamas, MPH, Medical Director

University of Cincinnati Continuing Medical Education Office
Robert V. Ellis, MD, Physician Reviewer
Susan P. Tyler, PhD, Director, Continuing Medical Education
Heather Muskopf, Program Manager

Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.